Company Filing History:
2 out of 13 
1 out of 5,313 
1 out of 1 Years Active: 2011-2023
Title: Debra Odink: Pioneering Innovations in Pharmaceuticals
Introduction: Debra Odink, a talented inventor based in Oakland, CA, has made significant contributions to the field of pharmaceuticals with her groundbreaking inventions. With a total of 3 patents to her name, Odink's work has focused on developing methods to treat hyperinsulinemic hypoglycemia using buffered formulations of exendin (9-39).
Latest Patents: Odink's latest patents revolve around liquid pharmaceutical formulations containing exendin (9-39) or its salts in a physiologically acceptable buffer with a pH range of about 5 to 6. These buffered formulations have shown promise in treating and preventing hyperinsulinemic hypoglycemia in subjects. Her innovative approach in formulating these treatments has garnered attention in the pharmaceutical industry.
Career Highlights: Odink's expertise has been honed through her work at esteemed institutions such as Eiger Biopharmaceuticals, Inc. and Stanford University. Her experience in both the corporate and academic settings has provided her with a well-rounded perspective on pharmaceutical research and development. Odink's dedication to improving healthcare through innovative solutions is evident in her patent portfolio.
Collaborations: Throughout her career, Debra Odink has collaborated with notable peers in the field, including Xiaofeng Xiong and Colleen M. Craig. These collaborations have led to the exchange of ideas and the development of novel approaches to tackling complex medical challenges. Odink's ability to work effectively in multidisciplinary teams has been instrumental in her success as an inventor.
Conclusion: Debra Odink's relentless pursuit of innovative solutions in pharmaceuticals has positioned her as a trailblazer in the industry. Her passion for improving patient care through cutting-edge research is evident in her patent portfolio and collaborations with top experts in the field. As she continues to push the boundaries of pharmaceutical innovation, Odink's work promises to have a lasting impact on healthcare practices worldwide.